Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
GKOS

Glaukos Corp

GKOS

62.26USD-2.76 (-4.24%)Market Closed
Watchlist

Market Summary

USD62.26-2.76
Market Closed
-4.24%

GKOS Alerts

  • Losses in recent quarter

GKOS Stock Price

View Fullscreen

GKOS RSI Chart

GKOS Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-23.45

Price/Sales (Trailing)

9.99

EV/EBITDA

-27.49

Price/Free Cashflow

-40.18

GKOS Price/Sales (Trailing)

GKOS Profitability

EBT Margin

-47.86%

Return on Equity

-27.37%

Return on Assets

-14.31%

Free Cashflow Yield

-2.49%

GKOS Fundamentals

GKOS Revenue

Revenue (TTM)

303.6M

Revenue Y/Y

9.51%

Revenue Q/Q

-2.92%

GKOS Earnings

Earnings (TTM)

-129.3M

Earnings Y/Y

-10.4%

Earnings Q/Q

7.22%

Price Action

Last 7 days

0.4%

Last 30 days

-2.7%

Last 90 days

-17.4%

Trailing 12 Months

41.3%

How does GKOS drawdown profile look like?

GKOS Financial Health

Current Ratio

6.67

GKOS Investor Care

Shares Dilution (1Y)

2.21%

Diluted EPS (TTM)

-2.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023289.1M296.8M303.6M0
2022293.7M288.3M284.9M282.9M
2021237.6M284.1M294.0M294.0M
2020238.3M211.3M217.6M225.0M
2019195.2M210.6M225.2M237.0M
2018163.5M165.4M168.9M181.3M
2017127.2M139.9M150.8M159.3M
201680.1M90.9M101.5M114.4M
201552.0M58.7M65.5M71.7M
201427.1M33.3M39.4M45.6M
201300020.9M

Latest Insider Trading transactions for GKOS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 02, 2023
burns thomas william
sold
-3,239,260
71.9836
-45,000
chairman & ceo
Oct 02, 2023
burns thomas william
acquired
327,375
7.275
45,000
chairman & ceo
Sep 14, 2023
navratil tomas
acquired
-
-
2,052
chief development officer
Sep 14, 2023
burns thomas william
acquired
-
-
4,169
chairman & ceo
Sep 08, 2023
gilliam joseph e
sold (taxes)
-72,030
74.72
-964
president & coo
Sep 08, 2023
burns thomas william
sold (taxes)
-285,580
74.72
-3,822
chairman & ceo
Sep 08, 2023
navratil tomas
sold (taxes)
-36,089
74.72
-483
chief development officer
Aug 04, 2023
kliman gilbert h
sold
-745,600
74.56
-10,000
-
Aug 04, 2023
kliman gilbert h
acquired
72,750
7.275
10,000
-
Aug 01, 2023
burns thomas william
sold (taxes)
-127,520
49.35
-2,584
chairman & ceo

1–10 of 50

Which funds bought or sold GKOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
added
12.85
315,596
1,954,920
-%
Nov 22, 2023
Public Sector Pension Investment Board
reduced
-29.73
-1,568,720
4,524,860
0.03%
Nov 22, 2023
KBC Group NV
unchanged
-
-
254,000
-%
Nov 21, 2023
COMERICA BANK
new
-
1,682,740
1,682,740
0.01%
Nov 21, 2023
Walleye Capital LLC
new
-
304,763
304,763
-%
Nov 15, 2023
Spouting Rock Asset Management, LLC
reduced
-12.42
-23,717
294,378
0.09%
Nov 15, 2023
Tudor Investment Corp Et Al
reduced
-80.48
-4,409,200
1,145,610
0.01%
Nov 15, 2023
JANE STREET GROUP, LLC
reduced
-73.73
-1,733,240
666,113
-%
Nov 15, 2023
MORGAN STANLEY
added
28.46
14,470,300
54,952,800
0.01%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
31.89
528,028
1,868,980
-%

1–10 of 37

Latest Funds Activity

Are funds buying GKOS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own GKOS
No. of Funds

Schedule 13G FIlings of Glaukos Corp

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
brown capital management llc
5.69%
2,712,809
SC 13G/A
Feb 14, 2023
burns thomas william
5.71%
2,807,641
SC 13G/A
Feb 09, 2023
vanguard group inc
11.21%
5,349,225
SC 13G/A
Feb 06, 2023
wellington management group llp
9.19%
4,385,656
SC 13G/A
Jan 31, 2023
blackrock inc.
16.3%
7,783,794
SC 13G
Feb 14, 2022
burns thomas william
5.65%
2,725,557
SC 13G/A
Feb 14, 2022
brown capital management llc
6.44%
3,021,796
SC 13G/A
Feb 04, 2022
artisan partners limited partnership
4.2%
1,983,513
SC 13G/A
Jan 28, 2022
blackrock inc.
15.8%
7,423,702
SC 13G/A
Jan 10, 2022
wellington management group llp
10.50%
4,923,297
SC 13G

Recent SEC filings of Glaukos Corp

View All Filings
Date Filed Form Type Document
Nov 01, 2023
8-K
Current Report
Nov 01, 2023
10-Q
Quarterly Report
Oct 04, 2023
4
Insider Trading
Oct 02, 2023
144
Notice of Insider Sale Intent
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 18, 2023
4
Insider Trading
Sep 12, 2023
4/A
Insider Trading
Sep 12, 2023
4
Insider Trading

Peers (Alternatives to Glaukos Corp)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
182.7B
40.0B
10.53% 1.10%
35.4
4.57
-11.26% -34.57%
71.3B
19.4B
-9.91% -3.76%
44.09
3.79
2.66% -16.58%
18.2B
15.0B
4.18% -29.75%
7.01
1.21
3.01% 209.09%
16.6B
3.8B
9.66% 16.57%
45.78
4.36
-1.48% -28.97%
MID-CAP
9.2B
12.7B
12.76% -12.43%
20.62
0.72
0.68% -30.25%
9.0B
2.7B
7.54% -22.26%
-56.74
3.32
-3.01% 97.36%
8.3B
3.4B
0.99% 18.16%
29.55
2.41
3.13% 18.17%
6.8B
3.9B
12.78% 6.97%
-31.29
1.73
-2.62% 73.28%
2.9B
342.6M
7.26% -12.48%
-242.59
8.48
42.19% 84.14%
2.5B
6.6B
-13.73% -8.33%
12.43
0.38
2.61% 0.62%
SMALL-CAP
1.1B
3.1B
0.24% -60.88%
-2.68
0.37
7.95% -550.16%
321.6M
163.3M
3.63% -28.72%
-13.09
1.97
7.14% -56.09%
271.9M
335.9M
0.60% -44.41%
42.18
0.81
4.71% 116.39%
77.6M
50.3M
-12.16% 23.08%
-5.12
1.54
3.23% 20.81%
5.3M
3.8M
10.99% -46.93%
-0.45
1.39
17.30% 10.67%

Glaukos Corp News

Latest updates
Orange County Business Journal04 Dec 202308:13 pm2 days ago
RealMoney03 Dec 202303:30 pm3 days ago
Nasdaq30 Nov 202309:18 pm6 days ago
Nasdaq30 Nov 202307:53 am7 days ago
Nasdaq23 Nov 202308:00 am14 days ago
Yahoo Finance01 Nov 202307:00 am36 days ago
Nasdaq01 Nov 202307:00 am36 days ago
Barchart01 Nov 202307:00 am36 days ago
Orange County Business Journal09 Oct 202307:00 am59 days ago
InvestorsObserver03 Oct 202307:00 am2 months ago
Orange County Business Journal11 Sep 202307:00 am2 months ago
Orange County Business Journal22 Aug 202307:00 am3 months ago
Barchart02 Aug 202307:00 am4 months ago
Orange County Business Journal26 Jun 202307:00 am5 months ago
Orange County Business Journal06 Feb 202308:00 am10 months ago

Financials for Glaukos Corp

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-2.9%78,048,00080,399,00073,899,00071,227,00071,269,00072,685,00067,681,00073,240,00074,710,00078,093,00067,968,00073,234,00064,831,00031,558,00055,336,00065,849,00058,509,00058,600,00054,026,00054,076,00043,908,000
Gross Profit-1.3%59,538,00060,296,00055,828,00054,005,00054,408,00054,852,00050,618,00056,375,00059,340,00060,334,00051,335,00053,644,00046,899,0009,890,00022,807,00049,945,00050,806,00050,730,00046,915,00046,958,00037,897,000
Operating Expenses-2.0%87,548,00089,371,00088,821,00087,739,00076,019,00091,612,00040,826,00074,244,00048,316,00074,556,00063,140,00065,036,00059,251,00057,087,00075,419,00079,642,00063,221,00056,970,00048,855,00045,061,00044,834,000
  S&GA Expenses2.1%54,247,00053,137,00053,650,00051,927,00047,149,00049,900,00043,949,00047,566,00044,470,00045,300,00041,921,00043,792,00038,947,00038,116,00050,546,00059,611,00044,443,00037,656,00034,925,00032,104,00031,632,000
  R&D Expenses-------26,877,000---21,219,000-------13,930,00012,957,00013,202,000
EBITDA Margin----0.41-0.28-0.24-0.040.05-0.02-0.06-0.08-0.24-0.39-0.64-0.58-0.37-0.17-----
Interest Expenses0.0%3,398,0003,399,0003,408,0003,409,0003,481,0003,414,0003,416,0003,424,0003,413,0003,306,0003,229,000----------
Income Taxes-90.7%37,000400,000401,000298,000247,000-105,000300,000-363,000202,000208,000279,000-3,243,000-889,000-7,384,000-450,000-65,841,000187,00072,000122,000530,00037,000
Earnings Before Taxes6.1%-30,407,000-32,377,000-34,225,000-31,162,000-27,329,000-45,641,0005,703,000-22,235,0006,432,000-17,274,000-16,190,000-13,891,000-16,637,000-47,278,000-54,508,000-29,260,000-13,319,000-6,237,000-1,220,0002,309,000-6,584,000
EBT Margin----0.48-0.35-0.31-0.19-0.09-0.17-0.14-0.23-0.40-0.59-0.68-0.68-0.43-0.21-----
Net Income7.2%-30,444,000-32,812,000-34,626,000-31,460,000-27,576,000-45,536,0005,377,000-21,872,0006,230,000-17,482,000-16,469,000-10,648,000-15,748,000-39,894,000-54,058,00036,581,000-13,506,000-6,309,000-1,342,0001,779,000-6,621,000
Net Income Margin----0.48-0.35-0.31-0.19-0.09-0.17-0.13-0.21-0.35-0.53-0.34-0.34-0.160.07-----
Free Cashflow----37,672,000-12,374,000-32,554,000-21,607,0003,170,000-13,986,0007,874,000-3,969,000-13,004,0008,447,000-10,851,000-13,650,000-13,881,000-5,416,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-0.8%9499579731,0021,0081,0311,0521,0501,0641,0441,0231,006995996780818307302228207191
  Current Assets-0.4%400401416444449471491486502491474469454453231263209201184177175
    Cash Equivalents21.1%11595.0076.0012010411211611012312810697.0090.0027663.0072.0048.0049.0042.0039.0037.00
  Inventory0.8%40.0039.0040.0038.0034.0028.0025.0023.0020.0018.0015.0016.0020.0021.0028.0043.0013.0014.0013.0013.0014.00
  Net PPE0.4%10310398.0094.0087.0081.0075.0069.0061.0054.0043.0024.0023.0023.0023.0022.0020.0020.0020.0019.0012.00
  Goodwill0%66.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.0066.00-----
Liabilities0.7%47146846447246046945546346345943333833333313814511711443.0033.0027.00
  Current Liabilities5.1%67.0064.0062.0072.0061.0070.0056.0063.0063.0034933650.0047.0055.0051.0058.0033.0031.0027.0030.0025.00
Shareholder's Equity-2.3%478489509530549562598587601584590667662662641673190188185174163
  Retained Earnings-5.7%-562-531-499-464-432-405-359-365-343-349-332-310-299-283-243-189-226-212-206-205-206
  Additional Paid-In Capital1.8%1,0391,0211,009997985972961952943933921977959944883862415399391378370
Shares Outstanding0.7%49.0048.0048.0048.0048.0047.0047.0047.0047.0046.0046.0045.0045.0044.0044.0044.0037.0036.0036.0036.0036.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-0.1%-8,168-8,161-30,764-4,136-26,515-12,2069,774-4,65117,7907,3914,17810,604-9,570-10,923-13,099-4,191-2,9886,60220817,1284,362
  Share Based Compensation6.2%10,4849,87310,18411,6889,41110,5396,9237,2256,1897,9848,7488,7449,66010,89717,17612,4708,5478,2477,1296,6687,173
Cashflow From Investing-42.6%14,89725,951-13,83216,65524,3919,630-5,897-8,872-26,063-2,034-21,263-3,459-181,562-20,66762849,812-4,074-599-1,713-17,752-5,932
Cashflow From Financing948.5%7,467-8801,1525294,2061061,4101,6173,86716,36217,4148,6595,821243,8424,220-22,0366,6663185,4071,97413,926

GKOS Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Net sales$ 78,048$ 71,269$ 232,346$ 211,635
Cost of sales18,51016,86156,68451,757
Gross profit59,53854,408175,662159,878
Operating expenses:    
Selling, general and administrative54,24747,149161,034140,998
Research and development33,30128,870101,70687,459
Acquired in-process research and development  3,00010,000
Litigation-related settlement   (30,000)
Total operating expenses87,54876,019265,740208,457
Loss from operations(28,010)(21,611)(90,078)(48,579)
Non-operating expense:    
Interest income2,7107446,2521,415
Interest expense(3,398)(3,481)(10,205)(10,311)
Other expense, net(1,709)(2,981)(2,978)(9,792)
Total non-operating expense(2,397)(5,718)(6,931)(18,688)
Loss before taxes(30,407)(27,329)(97,009)(67,267)
Income tax provision37247873468
Net loss$ (30,444)$ (27,576)$ (97,882)$ (67,735)
Basic net loss per share (in dollar per share)$ (0.63)$ (0.58)$ (2.03)$ (1.43)
Diluted net loss per share (in dollar per share)$ (0.63)$ (0.58)$ (2.03)$ (1.43)
Weighted average shares used to compute basic net loss per share48,67547,61448,28447,346
Weighted average shares used to compute diluted net loss per share48,67547,61448,28447,346

GKOS Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 108,929$ 119,525
Short-term investments191,928233,170
Accounts receivable, net39,32636,073
Inventory39,78137,841
Prepaid expenses and other current assets19,56517,250
Total current assets399,529443,859
Restricted cash5,8567,078
Property and equipment, net103,07594,403
Operating lease right-of-use assets27,27325,826
Finance lease right-of-use asset44,78646,601
Intangible assets, net289,184307,869
Goodwill66,13466,134
Deposits and other assets12,79710,613
Total assets948,6341,002,383
Current liabilities:  
Accounts payable10,41314,403
Accrued liabilities56,73457,956
Total current liabilities67,14772,359
Convertible senior notes282,430281,400
Operating lease liability30,57228,905
Finance lease liability70,78472,172
Deferred tax liability, net7,2497,264
Other liabilities12,79310,278
Total liabilities470,975472,378
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 150,000 shares authorized; 48,748 and 47,782 shares issued and 48,720 and 47,754 shares outstanding as of September 30, 2023 and December 31, 2022, respectively4948
Additional paid-in capital1,039,266997,470
Accumulated other comprehensive income (loss)764(2,975)
Accumulated deficit(562,288)(464,406)
Less treasury stock (28 shares as of September 30, 2023 and December 31, 2022)(132)(132)
Total stockholders' equity477,659530,005
Total liabilities and stockholders' equity$ 948,634$ 1,002,383
GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.
 CEO
 WEBSITEwww.glaukos.com
 EMPLOYEES783

Glaukos Corp Frequently Asked Questions


What is the ticker symbol for Glaukos Corp? What does GKOS stand for in stocks?

GKOS is the stock ticker symbol of Glaukos Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Glaukos Corp (GKOS)?

As of Wed Dec 06 2023, market cap of Glaukos Corp is 3.03 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GKOS stock?

You can check GKOS's fair value in chart. The fair value of Glaukos Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Glaukos Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GKOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Glaukos Corp a good stock to buy?

The fair value guage provides a quick view whether GKOS is over valued or under valued. Whether Glaukos Corp is cheap or expensive depends on the assumptions which impact Glaukos Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GKOS.

What is Glaukos Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, GKOS's PE ratio (Price to Earnings) is -23.45 and Price to Sales (PS) ratio is 9.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GKOS PE ratio will change depending on the future growth rate expectations of investors.